Floatz logo

Afnt-211

KRAS G12V

Affini-T Therapeutics, Inc.Cell therapyPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

19 Active assets in the KRAS G12V cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1/2CCC
Irinotecan
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1/2CCC
Calcium folinate pentahydrate
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1/2CCC
Cetuximab
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1/2CCC
Cyclophosphamide
Sun Yat-sen University
Phase 1CC

View all 19 →

Same molecule, other indications

Afnt-211 is also rated in:

pancreatic ductal adenocarcinomaDormant
CC
Indicative ·
41 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
40 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →